BioMimetix’s novel, proprietary metalloporphyrin (MnP) molecule for use in oncologic conditions is BMX-001. There is well defined Mechanism of Action, which includes:
Augmentation of DNA fragmentation and double the killing of tumor cells
Enhanced cysteine oxidation with increased apoptosis of tumor cells Inhibition of NFkB, which reduces the tumor survival response and inhibits inflammation in normal tissues
Activation of NRF-2, which turns on anti-inflammation pathways in normal tissue
Preferential accumulation of BMX-001 in tumor cells
Batinic-Haberle et al. Mn Porphyrin-Based Redox-Active Drugs:
Differential Effects as Cancer Therapeutics and Protectors of Normal Tissue Against Oxidative Injury.
Antioxid Redox Signal. 2018 Dec 1;29(16):1691-1724.. Epub 2018 Aug 28.
MoA: Combining MnP with Chemotherapy and Radiation Therapy to Maximize Tumor Cell Death
The combination of chemotherapy and radiotherapy with metalloporphyrins generates significantly greater DNA fragmentation and tumor cell death than any monotherapy.
BMX-001 – A Redox Active Metalloporphyrin (MnP)
Mn is the redox active center and is catalytic at near diffusion-limited rates
ROS lead to cellular damage and cancer death (by necrosis or apoptosis)
Tumor cells have enhanced accumulation of MnP compared to healthy cells
Mechanism of Action for Protection
of Normal Tissues
The above illustration shows that in normal tissues, oxidative stress has the effect of activating NFkB resulting in the release of pro inflammatory cytokines and at the same time activating the Nrf2 pathway, stimulating the production of anti-inflammatory enzymes which will control the inflammatory response. MnPs block the NFkB activation and further stimulate the Nrf2 pathway.